• Skip to primary navigation
  • Skip to main content
  • Skip to footer
MotherToBaby

MotherToBaby

Medications and More during pregnancy and breastfeeding

Buscar

Ocultar búsqueda
Shopping Cart
Mostrar búsquedaBuscar
866.626.6847
  • Acerca de
    • Nuestro Trabajo
    • Nuestro Equipo
    • Nuestros Colaboradores
    • Nuestro Impacto
  • Exposiciones
    • Exposiciones Durante el Embarazo y la Lactancia
    • Hojas Informativas
    • Baby Blogs
    • Podcasts
    • Herramienta interactiva
    • Otras Herramientas Educativas
    • App LactRx
  • Estudios
    • Estudios en Curso
    • ¿Qué Está Involucrado?
    • Unirse Ahora
    • Refiere a un Paciente
    • Profesionales de Salud
    • Industria Farmacéutica
    • Publicaciones
  • Profesionales de Salud
    • Educación para Pacientes y Recursos para Proveedores
    • Refiere un Paciente
    • Ordena Materiales
    • Reuniones
  • Medios de Comunicación
    • Solicitudes por los Medios
    • Comunicados de Prensa
    • Inscribirse para Boletín Electrónico
  • En Su Área
  • OTIS
    • Acerca de OTIS
    • Membresía de OTIS
    • Reunión Anual
  • Donar
  • Contactar
  • Mostrar búsquedaBuscar

Psoriasis and Psoriatic Arthritis

marzo 1, 2024

Selected References:

  • Bandoli G, et al. 2010 Potentially modifiable risk factors for adverse pregnancy outcomes in women with psoriasis. Br J Dermatol 163(2):334-339.
  • Ben-David G, et al. 2008. Pregnancy outcome in women with psoriasis. J Reprod Med 53(3):183-187.
  • Berman M, et al. 2018. The effect of pregnancy on disease activity in patients with psoriatic arthritis. J Rheumatol 45(12):1651-1655.
  • Bobotsis R, et al. 2016. Psoriasis and adverse pregnancy outcomes: a systematic review of observational studies. Br J Dermatol 175(3):464-472.
  • Bröms G, et al. 2018. Effect of maternal psoriasis on pregnancy and birth Outcomes: A population-based cohort study from Denmark and Sweden. Acta Derm Venereol 98(8):728-734.
  • Butler DC, et al. 2014. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. J Am Acad Dermatol 70(3):417.e1-10; quiz 427.
  • Caldarola G, et al. 2017. Untreated psoriasis impairs male fertility: A case-control study. Dermatology 233(2-3):170-174.
  • Carman WJ, et al. 2017. Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use. Pharmacoepidemiol Drug Saf 26(9):1109-1118.
  • Cohen-Barak E, et al. 2011. Pregnancy outcomes in women with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 25(9):1041-1047.
  • Eudy AM, et al. 2020. Pregnancy outcomes, fertility, and family planning in with psoriatic arthritis. Obstet Med. 13(2)70-75.
  • Gladman DD, et al. 2005. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64 Suppl 2:ii14-17.
  • Harder E, et al. 2014. No increased risk of fetal death or prolonged time to pregnancy in women with psoriasis. Invest Dermatol 34(6):1747-1749.
  • Huerta C, et al. 2007. Incidence and Risk Factors for Psoriasis in the General Population. Arch Dermatol 143(12):1559-1565.
  • Johansen CB, et al. 2022. Psoriasis and adverse pregnancy outcomes: A nationwide case-control study in 491,274 women in Denmark. JAAD Int 7: 146–155.
  • Kerola AM, et al. 2024. Patterns of reproductive health in inflammatory rheumatic diseases and other immune-mediated diseases: a nationwide registry study. Rheumatology (Oxford). keae122. PMID: 38503536.
  • Kimball AE et al. 2021. Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR) JAMA Dermatol 157(3): 1–6.
  • Meissner Y, et al. 2021. Pregnancy in women with psoriatic arthritis: A systematic literature review of disease activity and adverse pregnancy outcomes. Semin Arthritis Rheum 51(3):530-538.
  • Meserve J, et al. 2021. Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients with Immune-Mediated Inflammatory Diseases. Gastroenterology 161(1):107-115.
  • Lima XT, et al. 2012. The impact of psoriasis on pregnancy outcomes. J Invest Dermatol 132(1):85-91.
  • McMullan P, et al. 2024. Safety of dermatologic medications in pregnancy and lactation: An Update – Part I: Pregnancy. J Am Acad Dermatol.S0190-9622(24)00109-9.
  • Murase JE, et al. 2005. Hormonal effect on psoriasis in pregnancy & post-partum. Arch Dermatol 141(5):601-606.
  • Murase JE, et al. 2014. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol 70(3):401.e1-14.
  • Ostensen M. 1992. The effect of pregnancy on ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis. Am J Reprod Immunol 28(3-4):235-237.
  • Polachek A, et al. 2018. Outcome of pregnancy in women with psoriatic arthritis compared to healthy controls. Clinic Rheum 38: 895-902.
  • Rademaker M, et al. 2018. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. Australas J Dermatol 59(2):86-100.
  • Rahmati S, et al. 2023. Impact of maternal psoriasis on adverse maternal and neonatal outcomes: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 23(1):703.
  • Raychaudhuri SP, et al. 2003. Clinical course of psoriasis during pregnancy. Int J Dermatol 42(7):518-20.
  • Remaeus K, et al. 2019. Maternal and infant pregnancy outcomes in women with psoriatic arthritis: a Swedish nationwide cohort study. BJOG 126(10):1213-1222.
  • Seeger JD, et al. 2007. Pregnancy and pregnancy outcome among women with inflammatory skin diseases. Dermatol 214(1)32-39.
  • Smith C, et al. 2020. Birth outcomes and disease activity during pregnancy in a prospective cohort of women with psoriatic arthritis and ankylosing spondylitis. Amer Col Rheum 72(7):1029-1037
  • Tuğrul Ayanoğlu B, et al. 2018. Diminished ovarian reserve in patients with psoriasis. Taiwan J Obstet Gynecol 57(2):227-230.
  • Ursin K, et al. 2018. Disease activity of psoriatic arthritis during and after pregnancy: A prospective multicenter study. Arthritis Care Res (Hoboken) 71(8):1092-1100.
  • Yaghi M, et al. 2024. Safety of Dermatologic Medications in Pregnancy and Lactation: An Update – Part II: Lactation. J Am Acad Dermatol. S0190-9622(24)00110-5.
  • Yang YW, et al. 2011. Psoriasis and pregnancy outcomes: a nationwide population-based study. J Am Acad Dermatol 64(1):71-77.
  • Yiu ZZ, et al. 2014. Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients. Br J Dermatol 171(3):485-491.
  • Yiu ZZ, et al. 2015. Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes. J Dermatolog Treat 30:1-6.

Footer

               

Enlaces Candentes

  • Página Principal
  • Exposiciones
  • Hojas Informativas
  • Baby Blogs
  • Podcasts
  • Estudios de Embarazo
  • Unirse a un Estudio Ahora
  • Profesionales de Salud
  • Refiere un Paciente
  • Ordena Materiales
  • Comunicados de Prensa
  • Donar
  • Pregúntele a un Experto

Estudios en Curso

  • Espondilitis Anquilosante
  • Estreñimiento
  • Coronavirus (COVID-19)
  • Eccema (Moderado-a-Severo)/Dermatitis Atópica
  • Hidradenitis Supurative
  • Lupus
  • Esclerosis Múltiple
  • Psoriasis
  • Artritis Psoriásica

Contactar

Servicio de Información de Exposición
866.626.6847

Estudios de Embarazo
877.311.8972

Consultas de los Medios
619.368.3259
nchavez@mothertobaby.org

MotherToBaby, un servicio de la Organización de Especialistas en Información de Teratología

Derechos de autor © 2025 la Organización de Especialistas en Información de Teratología

  • Accesibilidad
  • Términos
  • Confidencialidad
  • Mapa del Sitio
^

MotherToBaby cuenta con el apoyo de la Administración de Recursos y Servicios de Salud (HRSA) del Departamento de Salud y Servicios Humanos de los Estados Unidos (HHS) como parte de una adjudicación por un total de $6,000,000 con cero porcentaje financiado con fuentes no gubernamentales. Los contenidos son los del autor/es y no representan necesariamente los puntos de vista oficiales de, ni un respaldo, por HRSA, HHS o el Gobierno de los Estados Unidos.